Section Arrow
XNCR.NASDAQ
- Xencor
Quotes are at least 15-min delayed:2025/05/23 00:51 EDT
Last
 7.69
+0.17 (+2.26%)
Day High 
7.705 
Prev. Close
7.52 
1-M High
12.43 
Volume 
1.01M 
Bid
7.81
Ask
8.76
Day Low
7.26 
Open
7.48 
1-M Low
7.46 
Market Cap 
535.20M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 8.21 
20-SMA 9.25 
50-SMA 10.13 
52-W High 27.24 
52-W Low 7.16 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.04/-2.51
Enterprise Value
715.70M
Balance Sheet
Book Value Per Share
8.99
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
110.49M
Operating Revenue Per Share
2.04
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PLRZPolyrizon Ltd0.0042-0.0012-22.22%-- 
NCNANuCana plc0.0394-0.001-2.48%-- 
BDRXBiodexa Pharmaceuticals plc1.39+0.09+6.92%-- 
VIGLVigil Neuroscience7.88+5.57+241.13%-- 
GERNGeron Corp1.48+0.14+10.45%-- 
Quotes are at least 15-min delayed:2025/05/23 00:51 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.